AbCellera Biologics (ABCL) is up ~35% in Monday morning trading after announcing top-line phase 2 data for ABCL635, its candidate for moderate-to-severe vasomotor symptoms (hot flashes) due to menopause.
The neurokinin 3 receptor (NK3R) antagonist antibody demonstrated statistically significant reductions in frequency
Welcome to AI Investor Picks, your trusted source for investment insights, financial strategies, and business opportunities. We are dedicated to providing cutting-edge information and analysis on a wide range of investment topics, including stocks, cryptocurrency, real estate, finance, and much more.
